SEC Form 4 · accession 0001209191-17-066233

GENOMIC HEALTH INC · GHDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Dec 14, 2017

Accepted (ET)

Dec 18, 2017 · 7:51 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001131324

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Dec 14, 2017	M	12,900	$17.33	A	54,819	D
Common Stock^F1	Dec 14, 2017	M	7,100	$17.18	A	61,919	D
Common Stock^F2,F3,F1	Dec 14, 2017	S	10,000	$30.00	D	51,919	D
Common Stock^F2,F3,F1	Dec 14, 2017	S	10,000	$33.00	D	41,919	D
Common Stock	holding	—	—		—	12,298	I	Held by Morgan Stanley as Custodian for Benefit of Kimberly Popovits
Common Stock	holding	—	—		—	16,825	I	Held in trust for the benefit of Ms. Popovits' son, of which Ms. Popovits is trustee.
Common Stock	holding	—	—		—	237,312	I	Held by the Popovits 2010 Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$17.33	Dec 14, 2017	M	12,900	D	—	Dec 4, 2018	Common Stock	0	0	D
Employee Stock Option (right to buy)^F5	$17.18	Dec 14, 2017	M	7,100	D	—	Feb 18, 2020	Common Stock	0	117,900	D

F1Includes an aggregate of 45,294 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 6, 2017.
F3Represents actual sale price.
F4The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.
F5The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.